Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Crystal S Denlinger

Showing results (71-80 of 98) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2012
Senior adult oncologyArti Hurria, Ilene S Browner, Harvey Jay Cohen, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Survivorship: sexual dysfunction (female), version 1.2013Crystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Survivorship: introduction and definition. Clinical practice guidelines in oncologyCrystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Survivorship: sleep disorders, version 1.2014Crystal S Denlinger, Jennifer A Ligibel, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Survivorship: sexual dysfunction (male), version 1.2013Crystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Pageof 10

Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With <i>RAS/BRAF</i> Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II TrialKanwal Pratap Singh Raghav, Katherine A Guthrie, Benjamin Tan, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2012
Senior adult oncologyArti Hurria, Ilene S Browner, Harvey Jay Cohen, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute WorkshopPaul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2019
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction AdenocarcinomaRonan J Kelly, Jeeyun Lee, Yung-Jue Bang, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 4, 2014
Survivorship: sexual dysfunction (female), version 1.2013Crystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 24, 2014
Survivorship: introduction and definition. Clinical practice guidelines in oncologyCrystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Survivorship: sleep disorders, version 1.2014Crystal S Denlinger, Jennifer A Ligibel, Madhuri Are, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 12, 2014
Survivorship: sexual dysfunction (male), version 1.2013Crystal S Denlinger, Robert W Carlson, Madhuri Are, et al.
Pageof 10